Equities

Arecor Therapeutics PLC

AREC:LSE

Arecor Therapeutics PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)77.50
  • Today's Change0.00 / 0.00%
  • Shares traded5.95k
  • 1 Year change42.20%
  • Beta0.4610
Data delayed at least 20 minutes, as of Feb 06 2026 10:41 GMT.
More ▼

Profile data is unavailable for this security.

About the company

Arecor Therapeutics plc is a United Kingdom-based globally focused biopharmaceutical company. The Company, by applying its technology platform, Arestat, is developing an internal portfolio of products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver therapeutic products. Its in-house development programs include AT278, Oral GLP-1 and AT247. AT278 is its ultra-concentrated, ultra-rapid acting insulin candidate. AT278 is designed to accelerate the absorption of insulin post injection even at very high concentrations (500U/mL). AT247 is designed to accelerate the absorption of insulin post injection. It is focused on the development of an oral GLP-1 receptor agonist (semaglutide). It has partnered with TRx Biosciences, combining its Arestat technology and TRx Biosciences' lipid technology, Lipicore, to target improved bioavailability of an oral GLP-1 receptor agonist. Its partnered programs include AT220, AT292 and AT351.

  • Revenue in GBP (TTM)5.06m
  • Net income in GBP-8.10m
  • Incorporated2021
  • Employees37.00
  • Location
    Arecor Therapeutics PLCChesterford Research ParkLittle ChesterfordSAFFRON WALDEN CB10 1XLUnited KingdomGBR
  • Phone+44 12 2342 6060
  • Websitehttps://arecor.com/
More ▼

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
Cizzle Biotechnology Holdings PLC0.00-1.12m6.14m67.006.14m67.00
Futura Medical PLC7.93m-6.29m7.41m12.007.41m12.00
OptiBiotix Health PLC1.15m-191.00k7.90m5.007.90m5.00
IXICO PLC6.53m-1.65m9.50m79.009.50m79.00
Genflow Biosciences PLC0.00-1.80m10.36m5.0010.36m5.00
Solvonis Therapeutics PLC0.00-2.60m17.02m--17.02m--
Fusion Antibodies PLC1.60m-1.47m20.00m24.0020.00m24.00
Sareum Holdings Plc0.00-4.44m23.47m5.0023.47m5.00
Arecor Therapeutics PLC5.06m-8.10m29.26m37.0029.26m37.00
Poolbeg Pharma PLC0.00-5.71m32.07m10.0032.07m10.00
ImmuPharma PLC0.00-3.93m32.07m6.0032.07m6.00
hVIVO PLC51.28m5.28m41.91m301.0041.91m301.00
Data as of Feb 06 2026. Currency figures normalised to Arecor Therapeutics PLC's reporting currency: UK Pound GBX

Institutional shareholders

27.72%Per cent of shares held by top holders
HolderShares% Held
BGF Investment Management Ltd.as of 07 Jun 20243.76m9.96%
Lombard Odier Asset Management (Europe) Ltd.as of 07 Jun 20241.94m5.15%
Chelverton Asset Management Ltd.as of 07 Jun 20241.42m3.77%
Unicorn Asset Management Ltd.as of 07 Jun 20241.20m3.17%
Foresight Group LLP (Investment Management)as of 31 Mar 20251.12m2.97%
Canaccord Genuity Wealth Ltd.as of 30 Sep 2025628.90k1.67%
Oberon Investments Ltd. (GB Investment Management)as of 31 Mar 2025389.90k1.03%
More ▼
Data from 30 Sep 2025 - 29 Jan 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.